We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+9.27%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+879.75%
AUM
$49B
AUM Growth
+$3.11B
(+6.8%)
Cap. Flow
+$228M
Cap. Flow
% of AUM
0.47%
Top 10 Holdings %
Top 10 Hldgs %
21.37%
Holding
1,104
New
303
Increased
294
Reduced
324
Closed
153
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$282M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$205M |
| 3 |
ConocoPhillips
COP
|
+$203M |
| 4 |
Fortive
FTV
|
+$200M |
| 5 |
Merck
MRK
|
+$178M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$665M |
| 2 |
ExxonMobil
XOM
|
+$332M |
| 3 |
Burlington
BURL
|
+$242M |
| 4 |
National Vision
EYE
|
+$186M |
| 5 |
CXO
CONCHO RESOURCES INC.
CXO
|
+$175M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.67% |
| 2 | Healthcare | 17.99% |
| 3 | Financials | 14.03% |
| 4 | Consumer Discretionary | 11.97% |
| 5 | Communication Services | 8.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SPRB
801
Spruce Biosciences
SPRB
$128M
| $4.82M | 0.01% |
3,873
| – | – |
|
|
BHVN
802
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $4.79M | 0.01% |
70,000
-80,000
| -53% | -$6.47M |
|
803
Hormel Foods
HRL
$13.8B
| $4.73M | 0.01% |
99,046
-205,900
| -68% | -$9.74M |
|
|
CHMA
804
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $4.7M | 0.01% |
1,500,000
-2,500,000
| -63% | -$9.59M |
|
|
PROS
805
DELISTED
ProSight Global, Inc.
PROS
| $4.66M | 0.01% |
370,000
+10,000
| +3% | +$127K |
|
|
KIN
806
DELISTED
Kindred Biosciences, Inc.
KIN
| $4.6M | 0.01% |
925,000
-750,000
| -45% | -$3.62M |
|
807
Myriad Genetics
MYGN
$304M
| $4.57M | 0.01% |
150,000
-41,310
| -22% | -$1.17M |
|
808
NRG Energy
NRG
$25.1B
| $4.57M | 0.01% |
121,035
-142,885
| -54% | -$5.69M |
|
809
Aurinia Pharmaceuticals
AUPH
$2.07B
| $4.55M | 0.01% |
350,110
-273,000
| -44% | -$3.96M |
|
|
AZPN
810
DELISTED
ASPEN TECHNOLOGY INC
AZPN
| $4.33M | 0.01% |
+30,000
| New | +$4.33M |
|
|
AJRD
811
DELISTED
Aerojet Rocketdyne Holdings
AJRD
| $4.23M | 0.01% |
90,000
| – | – |
|
812
DigitalOcean
DOCN
$14.4B
| $4.21M | 0.01% |
+100,000
| New | +$4.14M |
|
|
HSKA
813
DELISTED
Heska Corp
HSKA
| $4.21M | 0.01% |
+25,000
| New | +$4.43M |
|
|
AZEK
814
DELISTED
The AZEK Co
AZEK
| $4.21M | 0.01% |
+100,000
| New | +$4.28M |
|
|
XM
815
DELISTED
Qualtrics International Inc. Class A Common Stock
XM
| $4.11M | 0.01% |
+125,000
| New | +$5.07M |
|
816
Blink Charging
BLNK
$77.6M
| $4.11M | 0.01% |
+100,000
| New | +$4.36M |
|
817
Conagra Brands
CAG
$7.11B
| $4.07M | 0.01% |
108,145
-307,600
| -74% | -$10.9M |
|
818
Gilead Sciences
GILD
$162B
| $4.04M | 0.01% |
62,577
-1,400
| -2% | -$90.3K |
|
819
Allegion
ALLE
$14.3B
| $3.99M | 0.01% |
31,741
-44,833
| -59% | -$5.18M |
|
|
NINE
820
DELISTED
Nine Energy Service
NINE
| $3.92M | 0.01% |
1,705,076
-276,958
| -14% | -$832K |
|
821
Kymera Therapeutics
KYMR
$8.75B
| $3.89M | 0.01% |
100,000
| – | – |
|
|
TVRD
822
Tvardi Therapeutics
TVRD
$23.1M
| $3.8M | 0.01% |
+4,865
| New | +$3.33M |
|
|
NEX
823
DELISTED
NexTier Oilfield Solutions Inc.
NEX
| $3.72M | 0.01% |
1,000,000
+400,000
| +67% | +$1.62M |
|
824
CrowdStrike
CRWD
$211B
| $3.65M | 0.01% |
80,000
-120,000
| -60% | -$6.35M |
|
825
Zurn Elkay Water Solutions
ZWS
$8.6B
| $3.48M | 0.01% |
153,520
-1,867,420
| -92% | -$40.1M |
|
Similar funds
Adage Capital Partners's Q1 2021 Portfolio in Review
As of Q1 2021, Adage Capital Partners held 1,104 positions worth $49B, up 6.8% from $45.9B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Adage Capital Partners's Q1 2021 filing shows 303 new, 294 increased, 324 reduced and 153 closed positions. Its largest new stake was GW Pharmaceuticals Plc American Depositary Shares: 1,500,000 shares worth $325M. The largest sale was Royalty Pharma, an estimated $665M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 21% a quarter earlier, followed by Healthcare and Financials.
- Adage Capital Partners's largest Q1 2021 buy was GW Pharmaceuticals Plc American Depositary Shares: 1,500,000 shares worth $325M.
- Adage Capital Partners added most to Alexion Pharmaceuticals in Q1 2021, an estimated $205M increase.
- Adage Capital Partners's biggest Q1 2021 reduction was Royalty Pharma, cutting an estimated $665M.
- Adage Capital Partners fully exited CONCHO RESOURCES INC. in Q1 2021, selling an estimated $175M.
- Adage Capital Partners's ten largest holdings make up 21% of its $49B portfolio in Q1 2021.
- Adage Capital Partners opened 303 new positions and closed 153 in Q1 2021.
- Adage Capital Partners's portfolio value rose 6.8% quarter-over-quarter to $49B.
Based on Adage Capital Partners's 13F filing for Q1 2021, filed 17 May 2021.